Title 21, Food and DrugsRelease 119-110

§814 Removal of Exemption of Certain Drugs

Title 21 › CHAPTER 13 — DRUG ABUSE PREVENTION AND CONTROL › SUBCHAPTER I — CONTROL AND ENFORCEMENT › Part B — Authority To Control; Standards and Schedules › § 814

Last updated Sep 22, 2026|Official source

Summary

The Attorney General must remove a drug or group of drugs from its special exemption if they find people are taking the drug to get a listed chemical used to make illegal drugs. In deciding to remove an exemption, the Attorney General will look at how big, how long, and how important the diversion is; whether the drug’s form makes it hard to use for making illegal drugs; and whether the listed chemical can be easily recovered from the drug. Any removal must be as narrow as the evidence allows, unless there is proof the problem will spread to other drugs. A drug maker can ask the Attorney General to put a product back under the exemption if the maker shows it is made and sold in a way that stops diversion. The Attorney General will consider package size and packaging, how it is sold and advertised, any evidence of diversion, actions the maker took to stop diversion, and other health and safety factors. If a maker files a real application within 60 days after the exemption is removed, sales during the application review are not treated as regulated. If the application is denied, that safe period lasts 60 more days unless the Attorney General has evidence of diversion and tells the maker. The Attorney General can change or remove a reinstated exemption later if diversion is found or the facts change.

Full Legal Text

Title 21, §814

Food and Drugs, Source: USLM XML via OLRC

(a)Removal of exemption
The Attorney General shall by regulation remove from exemption under section 802(39)(A)(iv) of this title a drug or group of drugs that the Attorney General finds is being diverted to obtain a listed chemical for use in the illicit production of a controlled substance.
(b)Factors to be considered
In removing a drug or group of drugs from exemption under subsection (a), the Attorney General shall consider, with respect to a drug or group of drugs that is proposed to be removed from exemption—
(1)the scope, duration, and significance of the diversion;
(2)whether the drug or group of drugs is formulated in such a way that it cannot be easily used in the illicit production of a controlled substance; and
(3)whether the listed chemical can be readily recovered from the drug or group of drugs.
(c)Specificity of designation
The Attorney General shall limit the designation of a drug or a group of drugs removed from exemption under subsection (a) to the most particularly identifiable type of drug or group of drugs for which evidence of diversion exists unless there is evidence, based on the pattern of diversion and other relevant factors, that the diversion will not be limited to that particular drug or group of drugs.
(d)Reinstatement of exemption with respect to particular drug products
(1)Reinstatement
On application by a manufacturer of a particular drug product that has been removed from exemption under subsection (a), the Attorney General shall by regulation reinstate the exemption with respect to that particular drug product if the Attorney General determines that the particular drug product is manufactured and distributed in a manner that prevents diversion.
(2)Factors to be considered
In deciding whether to reinstate the exemption with respect to a particular drug product under paragraph (1), the Attorney General shall consider—
(A)the package sizes and manner of packaging of the drug product;
(B)the manner of distribution and advertising of the drug product;
(C)evidence of diversion of the drug product;
(D)any actions taken by the manufacturer to prevent diversion of the drug product; and
(E)such other factors as are relevant to and consistent with the public health and safety, including the factors described in subsection (b) as applied to the drug product.
(3)Status pending application for reinstatement
A transaction involving a particular drug product that is the subject of a bona fide pending application for reinstatement of exemption filed with the Attorney General not later than 60 days after a regulation removing the exemption is issued pursuant to subsection (a) shall not be considered to be a regulated transaction if the transaction occurs during the pendency of the application and, if the Attorney General denies the application, during the period of 60 days following the date on which the Attorney General denies the application, unless—
(A)the Attorney General has evidence that, applying the factors described in subsection (b) to the drug product, the drug product is being diverted; and
(B)the Attorney General so notifies the applicant.
(4)Amendment and modification
A regulation reinstating an exemption under paragraph (1) may be modified or revoked with respect to a particular drug product upon a finding that—
(A)applying the factors described in subsection (b) to the drug product, the drug product is being diverted; or
(B)there is a significant change in the data that led to the issuance of the regulation.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

Amendments

2006—Subsec. (e). Pub. L. 109–177 struck out subsec. (e). Text read as follows: “Pursuant to subsection (d)(1) of this section, the Attorney General shall by regulation reinstate the exemption with respect to a particular ephedrine, pseudoephedrine, or phenylpropanolamine drug product if the Attorney General determines that the drug product is manufactured and distributed in a manner that prevents diversion. In making this determination the Attorney General shall consider the factors listed in subsection (d)(2) of this section. Any regulation issued pursuant to this subsection may be amended or revoked based on the factors listed in subsection (d)(4) of this section.” 1996—Subsec. (e). Pub. L. 104–237 added subsec. (e).

Statutory Notes and Related Subsidiaries

Effective Date

of 1996 AmendmentAmendment by Pub. L. 104–237 not applicable to sale of any pseudoephedrine or phenylpropanolamine product prior to 12 months after Oct. 3, 1996, except that, on application of manufacturer of particular drug product, Attorney General may exercise sole and judicially unreviewable discretion to extend such

Effective Date

up to additional 6 months, see section 401(g) of Pub. L. 104–237, set out as a note under section 802 of this title.

Effective Date

Section effective on date that is 120 days after Dec. 17, 1993, see section 11 of Pub. L. 103–200, set out as an

Effective Date

of 1993 Amendment note under section 802 of this title.

Reference

Citations & Metadata

Citation

21 U.S.C. § 814

Title 21, Food and Drugs

Last Updated

Sep 22, 2026

Release point: 119-110